JP2019502722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502722A5 JP2019502722A5 JP2018537761A JP2018537761A JP2019502722A5 JP 2019502722 A5 JP2019502722 A5 JP 2019502722A5 JP 2018537761 A JP2018537761 A JP 2018537761A JP 2018537761 A JP2018537761 A JP 2018537761A JP 2019502722 A5 JP2019502722 A5 JP 2019502722A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- immune
- cell
- population
- low
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022010113A JP2022058761A (ja) | 2016-01-20 | 2022-01-26 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2024053449A JP2024081737A (ja) | 2016-01-20 | 2024-03-28 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281064P | 2016-01-20 | 2016-01-20 | |
| US62/281,064 | 2016-01-20 | ||
| US201662336339P | 2016-05-13 | 2016-05-13 | |
| US62/336,339 | 2016-05-13 | ||
| PCT/US2017/014408 WO2017127729A1 (en) | 2016-01-20 | 2017-01-20 | Compositions and methods for immune cell modulation in adoptive immunotherapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010113A Division JP2022058761A (ja) | 2016-01-20 | 2022-01-26 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502722A JP2019502722A (ja) | 2019-01-31 |
| JP2019502722A5 true JP2019502722A5 (https=) | 2020-02-27 |
| JP7616817B2 JP7616817B2 (ja) | 2025-01-17 |
Family
ID=59362673
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018537761A Active JP7616817B2 (ja) | 2016-01-20 | 2017-01-20 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2022010113A Pending JP2022058761A (ja) | 2016-01-20 | 2022-01-26 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2024053449A Pending JP2024081737A (ja) | 2016-01-20 | 2024-03-28 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010113A Pending JP2022058761A (ja) | 2016-01-20 | 2022-01-26 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2024053449A Pending JP2024081737A (ja) | 2016-01-20 | 2024-03-28 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11096964B2 (https=) |
| EP (1) | EP3405567A4 (https=) |
| JP (3) | JP7616817B2 (https=) |
| KR (1) | KR102878032B1 (https=) |
| CN (2) | CN116376826A (https=) |
| AU (2) | AU2017210031C1 (https=) |
| CA (1) | CA3010236A1 (https=) |
| SG (1) | SG11201805186VA (https=) |
| WO (1) | WO2017127729A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| EP3302423B1 (en) | 2015-06-04 | 2022-05-25 | Crititech, Inc. | Particle production system and particle collection device |
| EP3405568A4 (en) | 2016-01-20 | 2019-12-04 | Fate Therapeutics, Inc. | COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES |
| CA3010236A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| BR112018069628A2 (pt) | 2016-04-04 | 2019-02-12 | Crititech, Inc. | métodos para tratamento de tumor sólido |
| NZ750256A (en) | 2016-08-03 | 2026-02-27 | Dipersio John F | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| WO2018106595A1 (en) | 2016-12-05 | 2018-06-14 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CN110546265A (zh) | 2017-02-09 | 2019-12-06 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞及其组合物和方法 |
| EP3595683A1 (en) * | 2017-03-15 | 2020-01-22 | Orca Biosystems, Inc. | Compositions and methods for hematopoietic stem cell transplants |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| EP3615145B1 (en) | 2017-06-09 | 2024-05-15 | Crititech, Inc. | Compositions for use in the treatment of epithelial cysts by intracystic injection of antineoplastic particles |
| WO2018231908A1 (en) | 2017-06-14 | 2018-12-20 | Crititech, Inc. | Methods for treating lung disorders |
| KR20250057947A (ko) | 2017-10-03 | 2025-04-29 | 크리티테크, 인크. | 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달 |
| WO2019100079A1 (en) * | 2017-11-20 | 2019-05-23 | Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center | Compositions for improving car-t cell functionality and user thereof |
| EP3749753B1 (en) * | 2018-02-09 | 2025-04-02 | Immatics US, Inc. | Methods for manufacturing t cells |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| CN112243372A (zh) * | 2018-05-31 | 2021-01-19 | 克里蒂泰克公司 | 从受试者分离肿瘤特异性免疫细胞用于过继性细胞疗法的方法和癌症疫苗 |
| JP2022516389A (ja) * | 2018-05-31 | 2022-02-28 | ワシントン・ユニバーシティ | 血液悪性腫瘍を治療するためのゲノム編集インバリアントナチュラルキラーＴ（ｉＮＫＴ）細胞 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| CN109136276A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种rfft2细胞的构建方法 |
| US11596692B1 (en) * | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
| US12410402B2 (en) | 2018-11-21 | 2025-09-09 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (NK) cell subset and related compositions and methods |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| KR102943217B1 (ko) * | 2018-12-02 | 2026-03-25 | 페이트 세러퓨틱스, 인코포레이티드 | 향상된 iPSC 유래 효과기 세포를 사용한 면역요법 |
| JP2022518934A (ja) * | 2019-01-29 | 2022-03-17 | ジーピービー・サイエンティフィック・インコーポレイテッド | 向上した生産性および医薬的特徴を持つ細胞集団 |
| EP3924467A1 (en) * | 2019-02-15 | 2021-12-22 | Editas Medicine, Inc. | Modified natural killer (nk) cells for immunotherapy |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| JP2022525928A (ja) * | 2019-03-21 | 2022-05-20 | ガミダ セル リミテッド | 併用療法における移植に適したｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用 |
| KR20200122261A (ko) | 2019-04-17 | 2020-10-27 | (주)차바이오텍 | 항암 활성이 증가된 자연살해세포 및 그의 면역 치료 용도 |
| KR102300846B1 (ko) * | 2019-11-01 | 2021-09-09 | 서울대학교산학협력단 | 면역 활성 개선용 조성물 및 이의 방법 |
| US11801304B2 (en) | 2020-02-19 | 2023-10-31 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof |
| JP7493606B2 (ja) * | 2020-03-02 | 2024-05-31 | 中央研究院 | ナチュラルキラー細胞の増殖方法 |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| EP4200023A4 (en) | 2020-08-23 | 2024-10-30 | Applied StemCell, Inc. | Hla-f-modified cells and methods |
| EP4232567A1 (en) * | 2020-10-26 | 2023-08-30 | Shoreline Biosciences, Inc. | Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| WO2022187280A1 (en) * | 2021-03-01 | 2022-09-09 | Dana-Farber Cancer Institute, Inc. | Personalized redirection and reprogramming of t cells for precise targeting of tumors |
| CN117222414A (zh) | 2021-03-01 | 2023-12-12 | 脱落性治疗公司 | 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法 |
| CN114807044B (zh) * | 2021-04-30 | 2023-09-08 | 四川大学华西医院 | 一种具有高nkt细胞比例的car-cik细胞制备方法及应用 |
| US20240366806A1 (en) * | 2021-07-02 | 2024-11-07 | Case Western Reserve University | Adoptive immunotherapy compositions and methods of tracking |
| CN115997726B (zh) * | 2022-07-11 | 2024-11-22 | 济宁医学院附属医院 | 一种靶向脊髓前角运动神经元ampk的aman小鼠模型构建方法 |
| AU2023362749A1 (en) * | 2022-10-20 | 2025-06-05 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| AU2023362748A1 (en) * | 2022-10-20 | 2025-06-05 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| CN117316291B (zh) * | 2023-10-20 | 2024-08-09 | 南方医科大学南方医院 | 基于免疫治疗疗效与毒性关系的免疫调节基因分类方法 |
| CN118272305B (zh) * | 2024-04-29 | 2025-04-08 | 深圳泽医细胞治疗集团有限公司 | 一种免疫细胞的培养基及其应用 |
| CN118325837B (zh) * | 2024-06-12 | 2024-09-03 | 深圳市中佳生物医疗科技有限公司 | 中性粒细胞的无血清无基质细胞培养方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92382A (en) | 1988-11-23 | 1994-12-29 | Univ Michigan | Use of a ligand specific for CD28 in the manufacture of medicament |
| NZ501276A (en) | 1997-07-01 | 2000-10-27 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders |
| AU770867B2 (en) | 1999-08-13 | 2004-03-04 | Fumie Sato | Prostaglandin derivatives |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US20040175373A1 (en) | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| US20050075276A1 (en) | 2003-03-14 | 2005-04-07 | Christopher Rudd | Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses |
| CA2546353A1 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
| SG177981A1 (en) | 2005-05-18 | 2012-02-28 | Array Biopharma Inc | 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases |
| WO2007103901A2 (en) * | 2006-03-06 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer |
| BRPI0714409A2 (pt) | 2006-07-14 | 2013-03-12 | Novartis Ag | derivados de pirimidina como inibidores de alk-5 |
| EP2094837B1 (en) | 2006-12-14 | 2012-04-25 | Medical Research Council | Use of pi3k, m-tor and akt inhibitors to induce foxp3 expression and generate regulatory t cells |
| SG188904A1 (en) * | 2008-03-17 | 2013-04-30 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| CA2728739C (en) | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| EP4585589A3 (en) | 2008-12-03 | 2025-11-19 | The Scripps Research Institute | Stem cell cultures |
| CN102281761A (zh) * | 2009-01-14 | 2011-12-14 | 健康研究股份有限公司 | 用于增强免疫应答的方法和含有mTOR抑制剂的组合物 |
| EP3399026B1 (en) | 2010-06-14 | 2024-06-26 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| ES2791716T3 (es) * | 2010-12-14 | 2020-11-05 | Univ Maryland | Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer |
| EP2638896A1 (en) * | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| AU2014248119B2 (en) | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
| WO2015127548A1 (en) * | 2014-02-28 | 2015-09-03 | The Royal Institution For The Advancement Of Learning / Mcgill University | Tc-ptp inhibitors as apc activators for immunotherapy |
| US20170165230A1 (en) * | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| SI3151672T1 (sl) * | 2014-06-06 | 2021-03-31 | Bluebird Bio, Inc. | Izboljšani T-celični sestavki |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| US20180112180A1 (en) | 2015-01-26 | 2018-04-26 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| AU2016211671B2 (en) | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| JP2018509459A (ja) | 2015-03-27 | 2018-04-05 | ナントクエスト インコーポレイテッド | がん治療薬との併用療法におけるｎｋ−９２細胞 |
| WO2016179283A1 (en) | 2015-05-05 | 2016-11-10 | Fate Therapeutics, Inc. | Modulation of t lymphocytes |
| PT3294764T (pt) | 2015-05-15 | 2021-02-15 | Hope City | Composições de recetores de antigénios quiméricos |
| WO2017040324A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| EP3405568A4 (en) | 2016-01-20 | 2019-12-04 | Fate Therapeutics, Inc. | COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES |
| CA3010236A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| WO2018106595A1 (en) | 2016-12-05 | 2018-06-14 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CA3068604A1 (en) | 2017-06-13 | 2018-12-20 | Fate Therapeutics, Inc. | Compositions and methods for inducing myeloid suppressive cells and use thereof |
| CN111511762B (zh) * | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
-
2017
- 2017-01-20 CA CA3010236A patent/CA3010236A1/en active Pending
- 2017-01-20 CN CN202310345522.4A patent/CN116376826A/zh active Pending
- 2017-01-20 AU AU2017210031A patent/AU2017210031C1/en active Active
- 2017-01-20 JP JP2018537761A patent/JP7616817B2/ja active Active
- 2017-01-20 SG SG11201805186VA patent/SG11201805186VA/en unknown
- 2017-01-20 KR KR1020187020612A patent/KR102878032B1/ko active Active
- 2017-01-20 WO PCT/US2017/014408 patent/WO2017127729A1/en not_active Ceased
- 2017-01-20 US US16/071,457 patent/US11096964B2/en active Active
- 2017-01-20 CN CN201780007121.0A patent/CN108473959B/zh active Active
- 2017-01-20 EP EP17742046.0A patent/EP3405567A4/en active Pending
-
2020
- 2020-06-26 AU AU2020204267A patent/AU2020204267B2/en active Active
-
2021
- 2021-07-07 US US17/369,831 patent/US12281329B2/en active Active
-
2022
- 2022-01-26 JP JP2022010113A patent/JP2022058761A/ja active Pending
-
2024
- 2024-03-28 JP JP2024053449A patent/JP2024081737A/ja active Pending
-
2025
- 2025-03-20 US US19/085,376 patent/US20250215396A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502722A5 (https=) | ||
| JP2020528885A5 (https=) | ||
| JP2019502725A5 (https=) | ||
| JP7616817B2 (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| JP7664913B2 (ja) | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 | |
| JP2025038093A (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| JP2024123210A (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| JP2022550899A (ja) | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 | |
| IL293564A (en) | Enhancement of ipsc-derived effector immune cell using small compounds | |
| JP2024501020A (ja) | 操作されたガンマデルタｔ細胞ならびにその作製方法および使用方法 | |
| US20240358760A1 (en) | Primary T-Cell Expansion | |
| US20140037599A1 (en) | Compositions and Methods of Treating T Cell Deficiency | |
| KR20180063847A (ko) | 멀티플렉스 CRISPR-Cas9 시스템을 이용한 HLA 결핍 세포주로부터 제조된 인공항원제시세포 및 이의 용도 | |
| US20250368955A1 (en) | B cell lineages derived from pluripotent cells | |
| Yazdanparast et al. | CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization | |
| CN119452076A (zh) | 免疫细胞的产生 | |
| CN117979978A (zh) | 从干细胞产生经工程化的t细胞 | |
| CN117940139A (zh) | 对用于同种异体car t细胞疗法的干细胞进行工程化 | |
| US20260071180A1 (en) | Genetically engineered placental mucosalassociated invariant t (mait) cells and uses thereof | |
| Kögler et al. | Biology of umbilical cord blood cells | |
| HK40119436A (zh) | 基因工程化胎盘黏膜相关恒定t(mait)细胞及其用途 | |
| Melenhorst et al. | Tumor vaccines and beyond | |
| CN121896164A (zh) | 一种t细胞培养基、细胞培养物及其培养方法和应用 | |
| CN121896167A (zh) | 一种t细胞培养基、细胞培养物及其培养方法和应用 | |
| JP2024542151A (ja) | Ｎｋ細胞の生成法 |